Compound SYN045 soft capsule and preparation method thereof
By using a combination of vegetable oil and polyoxyethylene glyceryl oleate in soft capsule preparations, and optimizing the formulation of soft capsule shells, the problems of dissolution and stability of compound SYN045 were solved, and its bioavailability and efficacy were improved.
Patent Information
- Application Number
- CN202411091559.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-08-09
AI Technical Summary
Due to its poor solubility and strong hydrophobicity, compound SYN045 has problems such as slow dissolution, incompleteness and low bioavailability when preparing the compound SYN045, which limits its efficacy.
Using soft capsule preparations, the contents are formed by combining fixed proportions of vegetable oil and polyoxyethylene glycerol oleate, and the formula of soft capsule shells is optimized, glycerol and sorbitol are selected as plasticizers to reduce the migration of drugs to the capsule shells and avoid Crosslinking reactions affect drug release.
Soft capsule preparations with good drug dissolution have been achieved, drug content and bioavailability have been improved, product stability and quality have been enhanced, and clinical needs have been met.
Smart Images

Figure BDA0004986724420000051 
Figure BDA0004986724420000061 
Figure BDA0004986724420000071
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a compound SYN045 soft capsule and a preparation method thereof. Background Art
[0002] Pulmonary hypertension is a malignant disease characterized by increased pulmonary vascular resistance and pulmonary artery pressure caused by pulmonary artery lesions. In severe cases, it can lead to right heart failure or even death. The latest data show that the incidence and prevalence of pulmonary hypertension in adults are 0-6 cases and 48-55 cases per million, respectively. Due to the rapid progression of the disease, it has a high mortality rate and disability rate, and is regarded as a "malignant tumor" in the cardiovascular field. For the treatment of pulmonary hypertension, organizations such as the European Society of Cardiology mainly recommend that patients use targeted drugs. Targeted therapy aims to restore the imbalance of vasoactive mediators through the prostacyclin pathway, endothelin pathway and NO pathway. Currently used targeted drugs mainly include prostacyclin analogs, prostacyclin receptor agonists, ERA, PDE5i and sGC stimulators.
[0003] The compound SYN045, whose chemical name is 6-((5,6-diphenyl-1,2,4-triazine-3-yl)(isopropyl)amino)-N-(methylsulfonyl)hexanamide, is a small molecule compound with a brand-new structure. By optimizing the structure of the lead compound, the highly targeted and low-side-effect prostaglandin receptor (PGI2) agonist SYN045 was obtained. Preclinical studies have shown that it has a prominent antihypertensive effect and can significantly improve the symptoms related to pulmonary hypertension in rats with pulmonary hypertension models. At the same time, it improves the tolerated dose and survival rate of rats, has a high safety, and the target indication is pulmonary hypertension.
[0004] The compound SYN045 has poor solubility and strong hydrophobicity. Its solubility in aqueous solutions and buffers of different pH values is low. If it is prepared into ordinary oral solid preparations, such as tablets or capsules, there are problems such as slow and incomplete drug dissolution and low bioavailability, which limit its therapeutic effect. And because the compound SYN045 has high drug activity, the product specifications after being developed into a preparation will be very low.
[0005] Soft capsule preparations are suitable for poorly soluble drugs, especially for the packaging of low-dose, hydrophobic drugs, and have high content uniformity and high bioavailability. Therefore, it is necessary to develop a soft capsule preparation product of compound SYN045 to meet clinical needs. Summary of the invention
[0006] In view of this, the present invention provides a compound SYN045 soft capsule and a preparation method thereof.
[0007] An object of the present invention is to provide a compound SYN045 soft capsule, which consists of contents and a soft capsule shell, wherein the contents include the following components in percentage by mass: compound SYN045 0.02%-0.28%, vegetable oil 85.0%-91.5%, polyoxyethylene oleyl glyceride 8.0%-14.5%, preservative 0.05%-0.15% and antioxidant A 0.10%-0.30%; wherein the total percentage of the above components is 100%.
[0008] Optionally, the vegetable oil in the content is one or more of soybean oil, corn oil, peanut oil, olive oil or rapeseed oil.
[0009] In some embodiments, the preservative in the content is one or more of propylparaben, ethylparaben, paraben butyrate or benzoic acid.
[0010] In some embodiments, the antioxidant A in the content is one or more of butylated hydroxyanisole, butylated hydroxytoluene, vitamin E or propyl gallate.
[0011] The present invention adopts a combination of vegetable oil and polyoxyethylene oleyl glyceride in a fixed ratio to form contents, thereby obtaining a compound SYN045 soft capsule with good drug dissolution, high drug content, low impurity generation and high bioavailability.
[0012] Furthermore, during the storage and placement of the soft capsules containing the above contents, stability studies found that the drug ingredient compound SYN045 in the soft capsules easily migrated from the contents to the capsule shell, causing drug leakage and accelerating drug degradation, resulting in an increase in impurities and a decrease in the content of the active ingredient. The capsule shell formulation needs to be optimized.
[0013] In some embodiments, the soft capsule shell raw materials of the above-mentioned compound SYN045 soft capsule include the following components in percentage by mass: gelatin 44%-49%, plasticizer 16.0%-18.0%, sunscreen 0.60%-0.70%, antioxidant B 0.07%-0.09% and purified water 34%-38%; wherein the plasticizer is a mixture of glycerol and sorbitol; the mass ratio of glycerol to sorbitol is 1:2-3.
[0014] Optionally, the sunscreen in the soft capsule shell is titanium dioxide.
[0015] Furthermore, the antioxidant B in the soft capsule shell is one or both of glycine and sodium pyrosulfite.
[0016] The invention optimizes the prescription of the soft capsule shell, selects a plasticizer with a fixed ratio, and selects glycerol and sorbitol with a mass ratio of 1:2-3, thereby reducing the transfer of the compound SYN045 to the soft capsule shell, and avoiding the cross-linking reaction of the soft capsule shell to affect the drug release, thereby generally solving the quality stability problems of the soft capsule preparation during the storage process of the drug, such as low drug content, many impurities, poor dissolution, etc.
[0017] In a more preferred embodiment, the contents of the compound SYN045 soft capsules include the following components in percentage by mass: 0.22% of compound SYN045, 88.5% of soybean oil, 11% of polyoxyethylene olein, 0.09% of propyl paraben and 0.13% of butylated hydroxyanisole A.
[0018] In a more preferred embodiment, the soft capsule shell material of the above-mentioned compound SYN045 soft capsule comprises the following components in percentage by weight: 48% gelatin, 4.8% glycerol, 11.7% sorbitol, 0.62% titanium dioxide, 0.07% glycine and 34.5% purified water.
[0019] The second object of the present invention is to provide a method for preparing the above-mentioned compound SYN045 soft capsule, comprising the following steps:
[0020] S1. Take the prescribed amount of gelatin, glycerin, sorbitol, sunscreen, antioxidant B and purified water, stir at 65°C to 75°C to make gelatin, mix well, evacuate and remove bubbles for later use, and obtain a soft capsule shell solution;
[0021] S2, add the prescribed amount of polyoxyethylene oleyl glyceride and vegetable oil into the material tank, heat to 55 ° C ~ 65 ° C with stirring, add the prescribed amount of SYN045 raw material, preservative and antioxidant A, control the temperature at 55 ° C ~ 65 ° C and stir until completely dissolved, evacuate and remove bubbles for standby use, and obtain the soft capsule content liquid;
[0022] S3. Add the soft capsule shell solution and the soft capsule content liquid into the pill making machine, adjust the loading amount and the rubber thickness, press the pills, dry and package to obtain SYN045 soft capsules.
[0023] Furthermore, the sunscreen is titanium dioxide.
[0024] Furthermore, the antioxidant B is one or both of glycine and sodium pyrosulfite.
[0025] Furthermore, the vegetable oil is one or more of soybean oil, corn oil, peanut oil, olive oil or rapeseed oil.
[0026] Furthermore, the preservative is one or more of propylparaben, ethylparaben, parahydroxybenzoate or benzoic acid.
[0027] Furthermore, the antioxidant A is one or more of butylated hydroxyanisole, butylated hydroxytoluene, vitamin E or propyl gallate.
[0028] The present invention helps to accelerate the dissolution rate of the raw material drug by premixing the prescribed amount of polyoxyethylene olein and vegetable oil and then adding the compound SYN045. The optimized preparation process of the present invention is simple to operate, and also ensures product quality, which is conducive to industrial production and application. DETAILED DESCRIPTION
[0029] The present invention is further described in detail below through specific implementation modes, but it is only used to help understand the present invention so that professionals in the field can implement or use the present invention, and does not constitute any limitation to the present invention.
[0030] During the development of the new drug formulation of compound SYN045, it was found that the SYN045 raw material had poor solubility in water and strong hydrophobicity. In addition, due to its high activity, the dosage was low and the formulation specifications were small, which made its formulation development difficult. However, in the solubility study, it was unexpectedly found that the raw material had a high affinity for dissolving in vegetable oil matrices such as soybean oil and peanut oil, which could dissolve and encapsulate the drug, achieve precise control of the dosage, and effectively ensure the uniformity of the formulation content at extremely low formulation specifications, making it suitable for the development of soft capsule formulation products.
[0031] However, during the prescription screening, it was found that SYN045 was not stable enough in vegetable oil. By adding polyoxyethylene oleyl glyceride to the liquid medicine content, it helps to reduce the degradation of SYN045 in the liquid medicine content and ensure the stability of the active ingredient.
[0032] The present application is described below in conjunction with specific embodiments.
[0033] Example 1
[0034] Preparation of SYN045 soft capsules (1000 capsules)
[0035] A SYN045 soft capsule comprising the following components in percentage by mass:
[0036]
[0037] Preparation method:
[0038] 1. Take the above-prescribed amount of gelatin, glycerin, sorbitol, titanium dioxide, glycine and purified water, stir and gelatinize at 69℃~71℃ in a gelling tank, mix well, evacuate and remove bubbles for later use, and obtain a soft capsule shell solution;
[0039] 2. Add the prescribed amount of polyoxyethylene oleyl glyceride and soybean oil into the material tank, heat to 60°C-61°C and stir, add the prescribed amount of SYN045 API, propyl paraben and butylated hydroxyanisole, control the temperature at 59°C-60°C and stir until completely dissolved, evacuate and remove bubbles for standby use, and obtain the liquid medicine for the soft capsule contents;
[0040] 3. Add the soft capsule shell solution and the soft capsule content liquid into the pill making machine, adjust the filling amount and the thickness of the rubber, press the pills, dry and package to obtain SYN045 soft capsules.
[0041] Example 2
[0042] Preparation of SYN045 soft capsules (1000 capsules)
[0043] A SYN045 soft capsule comprising the following components in percentage by mass:
[0044]
[0045] Preparation method:
[0046] 1. Take the above-prescribed amount of gelatin, glycerin, sorbitol, titanium dioxide, glycine and purified water, stir and gelatinize at 65℃~68℃ in a gelling tank, mix well, evacuate and remove bubbles for later use, and obtain a soft capsule shell solution;
[0047] 2. Add the prescribed amount of polyoxyethylene oleyl glyceride and soybean oil into the material tank, heat to 55°C-57°C and stir, add the prescribed amount of SYN045 API, propylparaben and butylated hydroxyanisole, control the temperature at 55°C-58°C and stir until completely dissolved, evacuate and remove bubbles for standby use, and obtain the liquid medicine for the soft capsule contents;
[0048] 3. Add the soft capsule shell solution and the soft capsule content liquid into the pill making machine, adjust the filling amount and the thickness of the rubber, press the pills, dry and package to obtain SYN045 soft capsules.
[0049] Example 3
[0050] Preparation of SYN045 soft capsules (1000 capsules)
[0051] A SYN045 soft capsule comprising the following components in percentage by mass:
[0052]
[0053] Preparation method:
[0054] 1. Take the above-prescribed amount of gelatin, glycerin, sorbitol, titanium dioxide, glycine and purified water, stir and gelatinize at 73℃~75℃ in a gelatinization tank, mix well, evacuate and remove bubbles for later use, and obtain a soft capsule shell solution;
[0055] 2. Add the prescribed amount of polyoxyethylene oleyl glyceride and soybean oil into the material tank, heat to 62°C-65°C and stir, add the prescribed amount of SYN045 API, propyl paraben and butylated hydroxyanisole, control the temperature at 64°C-65°C and stir until completely dissolved, evacuate and remove bubbles for standby use, and obtain the liquid medicine for soft capsules;
[0056] 3. Add the soft capsule shell solution and the soft capsule content liquid into the pill making machine, adjust the filling amount and the thickness of the rubber, press the pills, dry and package to obtain SYN045 soft capsules.
[0057] Example 4
[0058] Preparation of SYN045 soft capsules (1000 capsules)
[0059] A SYN045 soft capsule comprising the following components in percentage by mass:
[0060]
[0061]
[0062] Preparation method:
[0063] 1. Take the above-prescribed amount of gelatin, glycerin, sorbitol, titanium dioxide, glycine and purified water, stir and gelatinize at 68℃~70℃ in a gelatinization tank, mix well, evacuate and remove bubbles for later use, and obtain a soft capsule shell solution;
[0064] 2. Add the prescribed amount of polyoxyethylene oleyl glyceride and soybean oil into the material tank, heat to 56°C-58°C and stir, add the prescribed amount of SYN045 API, propylparaben and butylated hydroxyanisole, control the temperature at 59°C-63°C and stir until completely dissolved, evacuate and remove bubbles for standby use, and obtain the liquid medicine for soft capsules;
[0065] 3. Add the soft capsule shell solution and the soft capsule content liquid into the pill making machine, adjust the filling amount and the thickness of the rubber, press the pills, dry and package to obtain SYN045 soft capsules.
[0066] Example 5
[0067] Preparation of SYN045 soft capsules (1000 capsules)
[0068] A SYN045 soft capsule comprising the following components in percentage by mass:
[0069]
[0070]
[0071] Preparation method:
[0072] 1. Take the above-prescribed amount of gelatin, glycerin, sorbitol, titanium dioxide, glycine and purified water, stir and gelatinize at 73℃~75℃ in a gelatinization tank, mix well, evacuate and remove bubbles for later use, and obtain a soft capsule shell solution;
[0073] 2. Add the prescribed amount of polyoxyethylene oleyl glyceride and corn oil into the material tank, heat to 55°C-56°C and stir, add the prescribed amount of SYN045 API, propyl paraben and butylated hydroxyanisole, control the temperature at 59°C-60°C and stir until completely dissolved, evacuate and remove bubbles for standby use, and obtain the liquid medicine for the soft capsule contents;
[0074] 3. Add the soft capsule shell solution and the soft capsule content liquid into the pill making machine, adjust the filling amount and the thickness of the rubber, press the pills, dry and package to obtain SYN045 soft capsules.
[0075] Example 6
[0076] Preparation of SYN045 soft capsules (1000 capsules)
[0077] A SYN045 soft capsule comprising the following components in percentage by mass:
[0078]
[0079]
[0080] Preparation method:
[0081] 1. Take the above-mentioned amount of gelatin, glycerin, sorbitol, titanium dioxide, glycine and purified water in a gelling tank at 69-71°C, stir and gelatinize, mix well, evacuate and remove bubbles for later use, and obtain a soft capsule shell solution;
[0082] 2. Add the prescribed amount of polyoxyethylene oleyl glyceride and peanut oil into the material tank, heat to 63°C-65°C and stir, add the prescribed amount of SYN045 API, ethyl p-hydroxybenzoate and butylated hydroxytoluene, control the temperature at 58°C-60°C and stir until completely dissolved, evacuate and remove bubbles for standby use, and obtain the liquid medicine for the soft capsule contents;
[0083] 3. Add the soft capsule shell solution and the soft capsule content liquid into the pill making machine, adjust the filling amount and the thickness of the rubber, press the pills, dry and package to obtain SYN045 soft capsules.
[0084] Example 7
[0085] Preparation of SYN045 soft capsules (1000 capsules)
[0086] A SYN045 soft capsule comprising the following components in percentage by mass:
[0087]
[0088]
[0089] Preparation method:
[0090] 1. Take the above-prescribed amount of gelatin, glycerin, sorbitol, titanium dioxide, sodium pyrosulfite and purified water, stir and gelatinize in a gel tank at 73°C to 75°C, mix well, evacuate and remove bubbles for later use, and obtain a soft capsule shell solution;
[0091] 2. Add the prescribed amount of polyoxyethylene oleyl glyceride and olive oil into the material tank, heat to 56°C-58°C and stir, add the prescribed amount of SYN045 API, p-hydroxyphenylbutyrate and vitamin E, control the temperature at 62°C-63°C and stir until completely dissolved, evacuate and remove bubbles for standby use, and obtain the liquid medicine of soft capsule contents;
[0092] 3. Add the soft capsule shell solution and the soft capsule content liquid into the pill making machine, adjust the filling amount and the thickness of the rubber, press the pills, dry and package to obtain SYN045 soft capsules.
[0093] Example 8
[0094] Preparation of SYN045 soft capsules (1000 capsules)
[0095] A SYN045 soft capsule comprising the following components in percentage by mass:
[0096]
[0097]
[0098] Preparation method:
[0099] 1. Take the above-prescribed amount of gelatin, glycerin, sorbitol, titanium dioxide, sodium pyrosulfite and purified water, stir and gelatinize in a gel tank at 72°C to 73°C, mix well, evacuate and remove bubbles for later use, and obtain a soft capsule shell solution;
[0100] 2. Add the prescribed amount of polyoxyethylene oleyl glyceride and rapeseed oil into the material tank, heat to 61°C-63°C and stir, add the prescribed amount of SYN045 API, benzoic acid and propyl gallate, control the temperature at 63°C-65°C and stir until completely dissolved, evacuate and remove bubbles for standby use, and obtain the liquid medicine for the soft capsule contents;
[0101] 3. Add the soft capsule shell solution and the soft capsule content liquid into the pill making machine, adjust the filling amount and the thickness of the rubber, press the pills, dry and package to obtain SYN045 soft capsules.
[0102] Example 9
[0103] Preparation of SYN045 soft capsules (1000 capsules)
[0104] A SYN045 soft capsule comprising the following components in percentage by mass:
[0105]
[0106] Preparation method:
[0107] 1. Take the above-mentioned amount of gelatin, glycerin, sorbitol, titanium dioxide, glycine and purified water in a gelling tank at 70℃~72℃, stir and gelatinize, mix well, evacuate and remove bubbles for later use, and obtain a soft capsule shell solution;
[0108] 2. Add the prescribed amount of polyoxyethylene oleyl glyceride and soybean oil into the material tank, heat to 55°C-56°C and stir, add the prescribed amount of SYN045 API, propyl paraben and butylated hydroxyanisole, control the temperature at 58°C-60°C and stir until completely dissolved, evacuate and remove bubbles for standby use, and obtain the liquid medicine for the soft capsule contents;
[0109] 3. Add the soft capsule shell solution and the soft capsule content liquid into the pill making machine, adjust the filling amount and the thickness of the rubber, press the pills, dry and package to obtain SYN045 soft capsules.
[0110] Example 10
[0111] Preparation of SYN045 soft capsules (1000 capsules)
[0112] A SYN045 soft capsule comprising the following components in percentage by mass:
[0113]
[0114] Preparation method:
[0115] 1. Take the above-mentioned amount of gelatin, glycerin, sorbitol, titanium dioxide, glycine and purified water in a gelling tank at 65℃~67℃, stir and gelatinize, mix well, evacuate and remove bubbles for later use, and obtain a soft capsule shell solution;
[0116] 2. Add the prescribed amount of polyoxyethylene oleyl glyceride and soybean oil into the material tank, heat to 61°C-62°C and stir, add the prescribed amount of SYN045 API, propyl paraben and butylated hydroxyanisole, control the temperature at 61°C-63°C and stir until completely dissolved, evacuate and remove bubbles for standby use, and obtain the liquid medicine for soft capsules;
[0117] 3. Add the soft capsule shell solution and the soft capsule content liquid into the pill making machine, adjust the filling amount and the thickness of the rubber, press the pills, dry and package to obtain SYN045 soft capsules.
[0118] Comparative Example 1
[0119] Preparation of SYN045 soft capsules (1000 capsules)
[0120] A SYN045 soft capsule comprising the following components in percentage by mass:
[0121]
[0122] The preparation method is the same as that in Example 1, except that the amount of polyoxyethylene oleyl glyceride in Example 1 is reduced, and the types and amounts of other raw and auxiliary materials are the same.
[0123] Comparative Example 2
[0124] Preparation of SYN045 soft capsules (1000 capsules)
[0125] A SYN045 soft capsule comprising the following components in percentage by mass:
[0126]
[0127] The preparation method is the same as that of Example 1, except that the polyoxyethylene olein in Example 1 is replaced by polyethylene glycol laurin, and the types and amounts of other raw materials and auxiliary materials are the same.
[0128] Comparative Example 3
[0129] Preparation of SYN045 soft capsules (1000 capsules)
[0130] A SYN045 soft capsule comprising the following components in percentage by mass:
[0131]
[0132]
[0133] The preparation method is the same as that of Example 1, except that the amount of sorbitol in Example 1 is reduced, and the types and amounts of other raw materials and auxiliary materials are the same.
[0134] Comparative Example 4
[0135] Preparation of SYN045 soft capsules (1000 capsules)
[0136] A SYN045 soft capsule comprising the following components in percentage by mass:
[0137]
[0138] The preparation method is the same as that in Example 1, except that the amount of sorbitol in Example 1 is increased, and the types and amounts of other raw materials and auxiliary materials are the same.
[0139] Comparative Example 5
[0140] Preparation of SYN045 soft capsules (1000 capsules)
[0141] A SYN045 soft capsule comprising the following components in percentage by mass:
[0142]
[0143] The preparation method is the same as that of Example 1, except that the sorbitol in Example 1 is replaced by propylene glycol, and the types and amounts of other raw materials and auxiliary materials are the same.
[0144] Test Example 1 Stability Study
[0145] In order to investigate the stability of the products, accelerated tests were carried out on the samples prepared in Examples 1-10 and Comparative Examples 1-5. The above products were placed in the same packaging under accelerated conditions (40°C ± 2°C, relative humidity 75% ± 5%), and samples were taken at 0 month and 6 months, respectively, to compare the changes in content, solubility and related substances. The results are shown in Table 1.
[0146] Content detection method:
[0147] Determined according to high performance liquid chromatography (General Rules 0512 of Part IV of the Chinese Pharmacopoeia 2020 Edition).
[0148] Solvent methanol-water (80:20)
[0149] Take 10 capsules of the test product, pour out the contents into a 100ml volumetric flask, and rinse the inside of the soft capsule shell with solvent, ensuring that the contents are completely poured into the volumetric flask, add an appropriate amount of solvent, dissolve by ultrasound, then add solvent to dilute to the scale, shake well, and filter.
[0150] Reference solution Take an appropriate amount of SYN045 reference substance, weigh accurately, add solvent to dissolve by ultrasonication and quantitatively dilute to make a solution containing about 60 μg per 1 ml, and shake well. The preparation of the compound SYN045 reference substance refers to patent CN202410701022.4.
[0151] The chromatographic conditions were as follows: octadecylsilane bonded silica gel was used as filler; 0.2% (v / v) formic acid aqueous solution-methanol (20:80) was used as mobile phase; the flow rate was 1 ml per minute; the column temperature was 30° C.; the detection wavelength was 280 nm; and the injection volume was 20 μl.
[0152] Determination method: Accurately measure the test solution and the reference solution, inject them into the liquid chromatograph respectively, and record the chromatogram. Calculate the peak area according to the external standard method. The content requirement is 90%-110%.
[0153] Related substance detection methods:
[0154] Determined according to high performance liquid chromatography (General Rules 0512 of Part IV of the Chinese Pharmacopoeia 2020 Edition).
[0155] Test solution Take an appropriate amount of the product content, weigh accurately, add mobile phase to dissolve and quantitatively dilute to make a solution containing about 0.5 mg of compound SYN045 per 1 mL, filter, and take the filtrate.
[0156] Chromatographic conditions: Column: Welchrom-C 18 Chromatographic column (4.6mmx200mm, 5μm); mobile phase: 0.1mol / L sodium dihydrogen phosphate solution (pH adjusted to 4.0 with phosphoric acid)-acetonitrile (55:45); flow rate: 1.0mL / min; detection wavelength: 280nm; injection volume: 20μL.
[0157] Determination method: Accurately measure the test solution, inject it into the liquid chromatograph, and record the chromatogram.
[0158] If there are impurity peaks in the chromatogram of the limit test solution, the total amount of impurities calculated by the area normalization method shall not exceed 1.5%, the single largest impurity shall not exceed 0.5%, and the single other impurity shall not exceed 0.2%.
[0159] Dissolution test method:
[0160] It was determined according to the dissolution and release method (General Rules 0931 Method 2 of Part IV of the Chinese Pharmacopoeia 2020 Edition) and high performance liquid chromatography (General Rules 0512 of Part IV of the Chinese Pharmacopoeia 2020 Edition).
[0161] Use 900ml of pH1.0 hydrochloric acid solution containing 0.3% SDS as the dissolution medium, and the rotation speed is 50 revolutions per minute. Take samples after 10min, 15min, 20min, and 30min respectively. Take the test solution and the reference solution, and measure the content at a wavelength of 280nm. Calculate the dissolution of each tablet at different times, and the dissolution requirement is ≥85% at 20min.
[0162] Table 1 Stability study test data
[0163]
[0164] Test conclusion:
[0165] The experimental study found that the samples prepared in Examples 1-10 had high content, few impurities, and good stability. After 6 months of accelerated experiment, the content of the active ingredient in the contents did not decrease significantly, which solved the problem of the active ingredient in the contents migrating to the soft capsule shell, and the impurities did not increase significantly. The total impurities were still less than 1.0%, the maximum single impurity was less than 0.5%, and the other single impurities were less than 0.2%, all of which met the impurity limit requirements in the quality standard. At the same time, the solubility of the samples was high and stable, and there was no problem of significant reduction in dissolution during storage. After 6 months of acceleration, the solubility of 15min was above 90%, meeting the requirement of 20min solubility ≥ 85%.
[0166] The amount of polyoxyethylene oleyl glyceride used in Comparative Example 1 is too low, resulting in a very low content of the preparation product, with a content of only 87.3% at 0 months, and many impurities, with a total impurity of 1.58%, a maximum single impurity of 0.61%, and other single impurities of 0.27%, which cannot meet the quality standard requirements, and the stability of the preparation is very poor. After 6 months of accelerated experiment, the content was significantly reduced to 81.0%, and the impurities increased significantly, with a total impurity of 2.02%, a maximum single impurity of 0.83%, and other single impurities of 0.35%. At the same time, the solubility is very low, with a 20min solubility of only 75.9%, which is far beyond the requirements of the quality standard, and the product quality cannot be guaranteed.
[0167] In Comparative Example 2, polyoxyethylene oleyl glyceryl was replaced with polyethylene glycol laurate glyceryl, resulting in a significantly lower content of the preparation product, with the content at 0 month being only 80.6%, and significantly more impurities, with total impurities of 2.11%, the largest single impurity of 0.86%, and other single impurities of 0.37%, which could not meet the quality standard requirements, and the stability of the preparation was very poor. After 6 months of accelerated experiment, the content was significantly reduced to 73.1%, and the impurities were significantly increased, with total impurities of 2.63%, the largest single impurity of 1.13%, and other single impurities of 0.49%. At the same time, the solubility was very low, with a 20min solubility of only 66.4%, which were far beyond the requirements of the quality standards, and the product quality could not be guaranteed.
[0168] The amount of sorbitol used in the soft capsule shell in Comparative Example 3 is too low, resulting in a significant decrease in the content of the active ingredient in the contents of the preparation product after a 6-month accelerated test, from 101.8% at 0 months to 76.6%, and the active ingredient in the contents migrated into the soft capsule shell; at the same time, the impurities increased. After 6 months of accelerated testing, the total impurities were 1.57%, the maximum single impurity was 0.63%, and the other single impurities were 0.26%, which could not meet the quality standard requirements; and the solubility was significantly reduced. After 6 months of accelerated testing, the 20min solubility was only 71.9%, which did not meet the quality standard requirements, and the product quality could not be guaranteed.
[0169] In Comparative Example 4, the amount of sorbitol used in the soft capsule shell is too high, and the soft capsule shell is prone to cross-linking reaction, which may cause a water-insoluble film to form on the inner or outer surface of the soft capsule shell during the dissolution process, resulting in prolonged disintegration time and decreased dissolution and release rate and degree of the contents. The 0-month sample had a solubility of only 79.2% in 20 minutes, and after 6 months of accelerated experiment, the 20-minute solubility was only 69.3%, both of which did not meet the requirements of the quality standards, and the product quality could not be guaranteed.
[0170] In Comparative Example 5, sorbitol used in the soft capsule shell was replaced with propylene glycol, resulting in a more significant decrease in the content of the active ingredient in the contents of the preparation product after 6 months of accelerated testing, from 102.5% at 0 months to 65.5%, and the active ingredient in the contents migrated into the soft capsule shell; at the same time, impurities increased. After 6 months of accelerated testing, the total impurities were 2.51%, the maximum single impurity was 1.08%, and other single impurities were 0.46%, which could not meet the quality standard requirements; and the solubility was significantly reduced. After 6 months of accelerated testing, the 20min solubility was only 62.0%, which did not meet the quality standard requirements, and the product quality could not be guaranteed.
[0171] In summary, the compound SYN045 soft capsules of the present invention have high content, few impurities and high dissolution. After 6 months of accelerated experiment, the total impurities are still less than 1.0%, the maximum single impurity is less than 0.5%, and other single impurities are less than 0.2%. The solubility is high, and the solubility at 15 minutes is more than 90%, which meets the requirement of "20 minutes dissolution ≥ 85%" in the quality standard, improves bioavailability, ensures the safety and effectiveness of clinical medication, and greatly improves product quality.
[0172] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A compound SYN045 soft capsule, the soft capsule consisting of content and a soft capsule shell, It is characterized in that The content includes the following components in percentage by mass: 0.02%-0.28% of compound SYN045, 85.0%-91.5% of vegetable oil, 8.0%-14.5% of polyoxyethylene oleyl glyceride, 0.05%-0.15% of preservative and 0.10%-0.30% of antioxidant A.
2. The compound SYN045 soft capsule according to claim 1, It is characterized in that The soft capsule shell raw material comprises the following components in percentage by mass: 44%-49% gelatin, 16.0%-18.0% plasticizer, 0.60%-0.70% sunscreen, 0.07%-0.09% antioxidant B and 34%-38% purified water; wherein the plasticizer is a mixture of glycerol and sorbitol; and the mass ratio of glycerol to sorbitol is 1:2-3.
3. The compound SYN045 soft capsule as claimed in claim 1, It is characterized in that The vegetable oil is one or more of soybean oil, corn oil, peanut oil, olive oil or rapeseed oil.
4. The compound SYN045 soft capsule according to claim 1, It is characterized in that The preservative is one or more of propylparaben, ethylparaben, p-hydroxybenzoate or benzoic acid.
5. The compound SYN045 soft capsule according to claim 1, It is characterized in that The antioxidant A is one or more of butylated hydroxyanisole, butylated hydroxytoluene, vitamin E or propyl gallate.
6. The compound SYN045 soft capsule as claimed in claim 2, It is characterized in that The sunscreen is titanium dioxide.
7. The compound SYN045 soft capsule as claimed in claim 2, It is characterized in that The antioxidant B is one or both of glycine and sodium pyrosulfite.
8. The compound SYN045 soft capsule as claimed in claim 2, It is characterized in that The vegetable oil in the content is soybean oil, the preservative is propyl paraben, the antioxidant A is butyl hydroxyanisole, and the content includes the following components in percentage by mass: 0.22% of compound SYN045, 88.5% of soybean oil, 11% of polyoxyethylene olein, 0.09% of propyl paraben and 0.13% of butyl hydroxyanisole; the sunscreen in the soft capsule shell is titanium dioxide, the antioxidant B is glycine, and the raw material of the soft capsule shell includes the following components in percentage by mass: 48% of gelatin, 4.8% of glycerol, 11.7% of sorbitol, 0.62% of titanium dioxide, 0.07% of glycine and 34.5% of purified water.
9. A method for preparing the compound SYN045 soft capsule according to any one of claims 1 to 8, It is characterized in that The following steps are involved: S1. Take the prescribed amount of gelatin, glycerin, sorbitol, sunscreen, antioxidant B and purified water, stir at 65°C to 75°C to make a gel, mix well, evacuate and remove bubbles for later use, and obtain a soft capsule shell solution; S2, add the prescribed amount of polyoxyethylene oleyl glyceride and vegetable oil into the material tank, heat to 55 ° C ~ 65 ° C with stirring, add the prescribed amount of SYN045 API, preservative and antioxidant A, control the temperature at 55 ° C ~ 65 ° C and stir until completely dissolved, evacuate and remove bubbles for standby use, and obtain the soft capsule content liquid; S3, adding the soft capsule shell solution and the soft capsule content liquid into a pill making machine, pressing the pills, drying and packaging to obtain SYN045 soft capsules.
10. The method for preparing the compound SYN045 soft capsule according to claim 9, It is characterized in that The sunscreen is titanium dioxide; and / or The antioxidant B is one or both of glycine and sodium pyrosulfite; and / or The vegetable oil is one or more of soybean oil, corn oil, peanut oil, olive oil or rapeseed oil; and / or The preservative is one or more of propylparaben, ethylparaben, p-hydroxybenzoate or benzoic acid; and / or The antioxidant A is one or more of butylated hydroxyanisole, butylated hydroxytoluene, vitamin E or propyl gallate.
Citation Information
Patent Citations
Formula of soft capsule shell
CN102225055A
Selexipag pharmaceutical composition and preparation method thereof
CN112220770A
Selexipag tablet and preparation method thereof
CN112472675A
Pharmaceutical composition of selepag and preparation method thereof
CN116392491A
Solid dispersion containing selepag as well as preparation method and application of solid dispersion
CN116785244A
